Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer Canada, the Canadian distributor of EpiPen and EpiPen Jr (0.3 and 0.15 mg epinephrine) Auto-Injectors, fully expects to meet the exceptional increase in demand on the Canadian market resulting from the nationwide recall of Sanofi's Allerject (epinephrine injection, USP).
Subscribe to our email newsletter
The recall is specific to the Allerject epinephrine auto-injector, manufactured by Sanofi and does not apply to EpiPen.
Pfizer Canada has already shipped its current EpiPen inventory to wholesalers to be made available to Canadian patients.
Patient safety is Pfizer’s top priority and we are working diligently to secure and distribute five times our usual monthly EpiPeninventory to replace the Allerject auto-injectors recalled from the market. We are pleased to confirm that starting the first week of November, several additional shipments of EpiPen and of EpiPen Jr will arrive in Canada, which will be sufficient to meet the unexpected increase in demand by month end.
About EpiPen
EpiPen and EpiPen Jr (0.3 and 0.15 mg epinephrine) Auto-Injectors ("EpiPen") are indicated for the emergency treatment of anaphylactic reactions in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions.
The EpiPen Auto-Injector is a disposable, pre-filled automatic injection device that administers epinephrine in the event of a severe allergic reaction.